Eating Too Many Eggs Increases Risk of Developing

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
281
Eating Too Many Eggs Increases Risk of Developing Diabetes

Globally, some of the most popular breakfast food includes eggs, be it boiled, poached or scrambled. However, new research shows that excessive consumption of eggs may increase your risk of diabetes.

The longitudinal study, which was conducted by researchers from the University of South Australia in collaboration with Qatar University and China Medical University, was carried out between 1991 and 2009. This was the first study to evaluate the consumption of eggs in a large number of Chinese adults.

The study discovered that individuals who consumed one or more eggs on a regular basis, which is equivalent to 50 grams, increased their risk of diabetes by 60%. Currently, diabetes prevalence in China is above 11%, which is more than the global average of 8.5%. Diabetes has developed into a serious public health concern in the country.

Diabetes has not only affected the health but also the economy of some countries, accounting for 10% of the world health expenditure. In China, costs related to diabetes have surpassed $109 billion.

Dr. Ming Li, an epidemiologist and public health expert, states that the increase in diabetes cases is a growing concern, especially in China where changes to the conventional Chinese diet are affecting health. Li adds that diet is a factor that contributes to the onset of type 2 diabetes. Therefore, understanding the various dietary factors that may affect the increasing prevalence of the disease is crucial.

In the past few decades, China has gone through a nutritional transition that’s seen a lot of individuals move from a more conventional diet consisting of vegetables and grains to a more processed diet comprising of energy-dense food, snacks and meat. In the same period of time, the consumption of eggs has also been increasing steadily, with the number of people eating eggs almost doubling in China, from 1991 to 2009.

The study’s aim was to evaluate the people’s egg consumption on a long-term basis as well as their risk of developing diabetes. This was determined by fasting blood glucose. The study discovered that consuming more than 38 grams of eggs per day increased the diabetes risk in Chinese adults by nearly 25%.

Moreover, as stated above, grown-ups who ate more than 50 grams of eggs every day (one egg), grew their risk of getting diabetes by 60%. The impact was found to be more evident in women. Li noted that more research is required to look into the causal relationships.

A player in the biomedical field that you need to pay attention to is Processa Pharmaceuticals Inc. (NASDAQ: PCSA). This company specializes in advancing drug candidates that are at the stage of undergoing clinical trials.

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

Processa Pharmaceuticals, Inc. (PCSA) Stock Research Links

PCSA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CaliberMRI Revolutionizes Preclinical MRI with New Phantom

Updated Category News Views 107

CaliberMRI: Pioneers Shaping the Future of MRI Hot off the press, folks—CaliberMRI, known for setting the bar high in MRI standardization, has unleashed a new beast on the scene. Enter Model 340, a preclinical quantitative MRI phantom, ready to knock the socks off high-field systems. They’re talking 4.7T, 7T, and a jaw-dropping 9.4T compatibility here. This isn't just...

Continue Reading
LINE-X Seeks Veterans to Propel Franchise Growth

Updated Category News Views 55

If you've ever wondered about the intersection of military discipline and entrepreneurial spirit, LINE-X is handing veterans the keys, quite literally. With a nod to leathernecks and GIs, they're slashing their franchise fee by 25% for U.S. veterans aiming to trade sergeants' stripes for business clout. Franchising for Veterans: A Tailored Offer So, the word on the street...

Continue Reading
Peanuts and Diabetes: A Surprising Health Link

Updated Category News Views 68

A Nutty Approach to Diabetes Prevention Who would've thought peanuts could pack such a punch against diabetes? Amid the usual suspects of healthy foods, it's these humble legumes that are making headlines. The Peanut Institute, backed by fresh research, is shining a spotlight on their potential role in preventing type 2 diabetes, a disease that's affecting roughly 40...

Continue Reading
Untapped $41B VA Loan Potential: Opportunities Missed

Updated Category News Views 106

VA Loans: Unused Potential Sits at $41 Billion Are you telling me we're leaving $41 billion just sitting on the table in the form of untapped VA loans? That's the figure staring us in the face according to Veterans United's latest analysis. It's not just about numbers; it's a head-scratcher given the growing VA loan market share, which hit 10% last year. Where's the...

Continue Reading
Key Insights Await in Sectra's Six-Month Report

Updated Category News Views 75

Sometimes the anticipation of a financial report presentation feels akin to waiting for a storm to pass or the sun to finally break through after what seems like endless rain. That’s the kind of vibe we're getting from Sectra's upcoming six-month report presentation. Slated for November 25, President Torbjörn Kronander and CFO Jessica Holmquist will be stepping up to...

Continue Reading
AI Shakes Up Boat Discovery: Traffic Soars for Leaders

Updated Category News Views 28

AI's Surge in the Boating World Well, look who’s riding the AI wave—it's our old friends at Boat Trader and YachtWorld, leaving the competition coughing in their slipstream. Similarweb data throws some cold, hard fish onto the deck, showing these two raking in over 17 times the AI-referred traffic compared to their closest peers. If you’re sniffing around for where...

Continue Reading
Accro's Vitiligo Trial Moves Fast with Fosun's Boost

Updated Category News Views 112

Launching into Vitiligo Treatment Trials I'll tell you, the biotech world isn't for the faint-hearted, especially when you're juggling hefty terms like 'TYK2/JAK1'. But here we are, watching Accro Bioscience and Fosun Pharma dive headlong into the vitiligo space with this Phase II/III trial of AC-201. They've bagged the IND clearance, and now the first patient is in the...

Continue Reading
CPC Biotech Debuts Quattroflow HTX Pump Drive

Updated Category News Views 51

Innovative Moves in Bioprocessing Let's get one thing clear right off the bat—CPC Biotech, part of Dover (NYSE: DOV), just sent a signal loud and clear with their new Quattroflow HTX all-in-one pump drive. With a slick touchscreen, flexible control options, and self-touting accuracy, this thing sounds like it's set to change the game for biopharmaceutical processing....

Continue Reading
AI Adoption Institute Targets ROI with Peer Circles

Updated Category News Views 73

Transforming AI from Cost to Profit Alright folks, we all know AI's the flashy tool everyone's jumping on like it's the latest tech bandwagon. But here’s the raw deal: most of these shiny AI investments ain't paying back a damn thing. Enter the AI Adoption Institute (AiAi)—a new player in Denver aiming to salvage this mess and make AI about actual returns. Peering...

Continue Reading
Bramshill Fund Takes Top Spot in 2026 Fund Awards

Updated Category News Views 78

Another Feather in Bramshill's Cap They've done it again, folks. The Bramshill Multi-Strategy Income Fund has just snagged the 40 Act Fund of the Year award at the 2026 Hedge Fund Performance Awards. This ain't just another plaque for the wall; it's a nod to some serious heavy lifting by the folks handling this beast of a portfolio. The award, dished out by With...

Continue Reading

Top 5 Most Recently Viewed Articles

Twilio's Q4 Results Spark Diverse Analyst Reactions

Updated Category News Views 232

Twilio Inc Fourth Quarter Overview Twilio Inc reported notable financial results for the fourth quarter, capturing the attention of several analysts within the market. The company’s performance has sparked diverse reactions, particularly regarding its future guidance and the evolving role of artificial intelligence within its operations. Market Response to Q4 Earnings...

Continue Reading
FHLBank Indianapolis Dividends for Second Quarter of 2025

Updated Category News Views 180

FHLBank Indianapolis Declares Second Quarter Dividends FHLBank Indianapolis recently announced its second quarter dividends for 2025, detailing robust financial strategies and growth, as reflected in the declared dividends on Class B-2 activity-based capital stock and Class B-1 non-activity-based stock. These dividends have been set at annualized rates of 9.50% and 4.50%,...

Continue Reading
Neurogen Biomarking Partners with Quanterix for Alzheimer's Testing

Updated Category News Views 255

Revolutionizing Alzheimer's Detection with Neurogen Biomarking Neurogen Biomarking is making significant strides in the healthcare landscape by introducing a pioneering blood test aimed at the early detection of Alzheimer's disease and Mild Cognitive Impairment (MCI). This innovative approach leverages advanced biomarker technology developed by Quanterix Corporation,...

Continue Reading
Kepler Robotics Launches Innovative Humanoid Robot for Industries

Updated Category News Views 296

Revolutionizing Industries with the K2 Bumblebee Shanghai Kepler Robotics Co., Ltd has excitedly announced the commencement of mass production of its K2 "Bumblebee" model, confirming that the world's first commercially available hybrid-architecture humanoid robot is now shipping to eager customers. Milestone in Humanoid Robotics This significant development not only marks...

Continue Reading
Syntara Limited Reveals Groundbreaking Data in Myelofibrosis Trials

Updated Category News Views 259

Positive Interim Data from Syntara's Clinical Trials Syntara Limited, known for its innovative approach in drug development, has unveiled promising interim data concerning its ongoing Phase 2 study of SNT-5505. This clinical trial focuses on myelofibrosis, a complex bone marrow disorder that often leads to severe health complications. Details of the Clinical Trial The...

Continue Reading